Related Experiment Video
Updated: Feb 28, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient
Johanna Denman1, Kaveh Manavi1, Mark Cook1
1Genitourinary Medicine, Queen Elizabeth Hospital, Birmingham, UK.
Abstract:
We present a case of an HIV-positive man with systemic immunoglobulin light chain (AL) amyloid with cardiac involvement. At relapse, he was treated with lenalidomide and dexamethasone having previously developed autonomic neuropathy with bortezomib-based chemotherapy. The patient achieved a serological complete response with symptomatic improvement. After 11 cycles, lenalidomide was discontinued due to extensive ischaemia of the gastrointestinal tract. The patient remains symptomatically stable with normal levels of serum-free light chains 11 months after the treatment was discontinued. Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Retrovirus Life Cycles
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Treatment Resistant Cancers
Drugs for Treatment of Ulcerative Colitis in IBD

